gabapentin and pregabalin are associated with severe copd exacerbations gabapentin facial twitching

Gabapentinoid use, namely gabapentin and pregabalin, was associated with increased risk for severe chronic obstructive pulmonary disease (COPD) exacerbation in patients with epilepsy, A population-based cohort study of more than 10,000 persons using gabapentinoids found that their use was associated with an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation. PURPOSE: Recent evidence suggests an association between the use of gabapentinoids (gabapentin and pregabalin) and more frequent and clinically severe chronic obstructive pulmonary disease (COPD) exacerbations. 1 Hence, we aim to investigate a potential association of commonly prescribed muscle relaxants, including cyclobenzaprine and Compared with nonuse, gabapentinoid use was associated with increased risk for severe COPD exacerbation across the indications of epilepsy (HR, 1.58 [95% CI, 1.08 to 2.30]), neuropathic pain (HR, 1.35 [CI, 1.24 to 1.48]), and other chronic pain (HR, 1.49 [CI, 1.27 to 1.73]) and overall (HR, 1.39 [CI, 1.29 to 1.50]). Gabapentinoid use was associated with a significantly increased COPD exacerbation risk for each group of users compared with nonusers, with hazard ratios of 1.58, 1.35, and 1.49 for epilepsy Gabapentin did not differ from pregabalin in risk for severe COPD exacerbations. Comment: Although this study has typical limitations of a retrospective cohort design, it affirms reported cases of respiratory problems related to these medications and parallels anaesthesia-setting cohort studies that have suggested respiratory depression In patients with COPD, gabapentinoid use was associated with increased risk for severe exacerbation. These findings support the warnings from regulatory agencies and highlight the importance of considering this potential risk when prescribing gabapentin and pregabalin to patients with COPD. In patients with COPD, gabapentinoid use was associated with increased risk for severe exacerbation. This study supports the warnings from regulatory agencies and highlights the importance of considering this potential risk when prescribing gabapentin and pregabalin to patients with COPD. Gabapentinoid use was associated with an increased risk of severe COPD exacerbations (hazard ratio, 1.39; 95% CI, 1.29-1.50) across all indications. In patients with neuropathic and other chronic pain, the elevated risk persisted regardless of opioid or benzodiazepine use at entry. Use of gabapentinoids was associated with increased risk for severe COPD exacerbation in those with epilepsy (hazard ratio [HR], 1.58; 95% CI, 1.08-2.30), neuropathic pain (HR, 1.35; 95% CI, 1.24-1.48), other chronic pain (HR, 1.49; 95% CI, 1.27-1.73), and overall (HR, 1.39; 95% CI, 1.29-1.50). Gabapentinoids are associated with an increased risk of severe exacerbation in people with chronic obstructive pulmonary disease (COPD), a study of more than 10 000 people has reported. 1 Gabapentinoid use was associated with significantly higher risk for severe COPD exacerbations requiring hospitalization (15.1% vs. 8.3% annually; adjusted hazard ratio, 1.4). The researchers found that gabapentinoid use was associated with an increased risk for severe COPD exacerbations compared with nonuse overall (hazard ratio, 1.39) and across the indications of epilepsy, neuropathic pain, and other chronic pain (hazard ratios, 1.58, 1.35, and 1.49, respectively). The authors found that compared with nonuse, gabapentinoid use was associated with an increased risk for severe COPD exacerbation among users taking these drugs for epilepsy, neuropathic pain, and This population-based cohort study evaluated the risk of severe chronic obstructive pulmonary disease (COPD) exacerbation in patients receiving gabapentinoids (gabapentin and pregabalin) for neuropathic pain. Gabapentinoid use was associated with a higher risk for severe COPD exacerbation (HR, 1.39; 95% CI, 1.29–1.50). By Debbie Bunch. January 22, 2024. Gabapentinoids Associated with Severe COPD Exacerbations. A population-based study published by the Annals of Internal Medicine suggests COPD patients who take gabapentinoid drugs such as gabapentin and pregabalin are at increased risk for severe COPD exacerbations. Use of gabapentinoids (gabapentin, pregabalin) by people with chronic obstructive pulmonary disease (COPD) was associated with a 39% increased risk for severe disease exacerbation, according to investigators from McGill University and Lady Davis Institute for Medial Research in Montreal, Canada. In patients with COPD, gabapentinoid use was associated with increased risk for severe exacerbation. These findings support the warnings from regulatory agencies and highlight the importance of Gabapentin and pregabalin did not differ. Bottom line: In patients with COPD, gabapentinoid use is associated with severe exacerbations of COPD, which supports recent warnings from regulatory agencies. “In patients with COPD, gabapentinoid use was associated with increased risk for severe exacerbation,” the authors wrote. “This study supports the warnings from regulatory agencies and highlights the importance of considering this potential risk when prescribing gabapentin and pregabalin to patients with COPD.”

gabapentin and pregabalin are associated with severe copd exacerbations gabapentin facial twitching
Rating 5 stars - 550 reviews




Blog

Articles and news, personal stories, interviews with experts.

Video